Table 3.
Cost effectiveness of several strategies for the detection of LS among newly diagnosed CRC cases. The strategies arranged in order of effectiveness (yield- # of LS cases identified among 150,000) from low to high. Cost effectiveness is measured by incremental cost-effectiveness ratio (ICER) compared to the least costly strategy (#1).
| Strategy | Mean Cost Per LS Detected | Incremental Cost (Compared with Least | Effectiveness (yield) | Incremental Effectiveness | ICER |
|---|---|---|---|---|---|
| #3 | $21,757 | - | 3605 | - | - |
| #4 | $26,654 | $4,897 | 3626 | 21 | $233 |
| #6 | $72,232 | $50,475 | 3963 | 358 | $141 |
| #2 | $23,480 | $1,723 | 3974 | 369 | $5 |
| #7 | $80,803 | $59,046 | 3986 | 381 | $155 |
| #1 | $51,612 | $29,855 | 4074 | 469 | $64 |
| #9 | $88,737 | $66,980 | 4368 | 763 | $88 |
| #8 | $85,881 | $64,124 | 4370 | 765 | $84 |
| #10 | $88,737 | $66,980 | 4392 | 787 | $85 |
| #5 | $207,705 | $185,948 | 4478 | 873 | $213 |